TNF Pharmaceuticals (NASDAQ:TNFA) Hits New 12-Month Low - Should You Sell?

Key Points

• TNF Pharmaceuticals shares reached a new 52-week low at $4.38, with the last trading price at $4.53, down 20.3% from the previous close of $4.83.
• The company's market cap stands at $687.69 million with a price-to-earnings ratio of -1.67, indicating significant losses.
• TNF Pharmaceuticals is focused on developing novel therapeutic platforms, including MYMD-1, which targets chronic inflammation by regulating the immune system.

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA - Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $4.38 and last traded at $4.53, with a volume of 305808 shares traded. The stock had previously closed at $4.83.

TNF Pharmaceuticals Stock Down 20.3%

The firm has a market cap of $687.69 million, a price-to-earnings ratio of -1.67 and a beta of 2.05. The company's 50-day moving average price is $10.48 and its 200-day moving average price is $21.45.

TNF Pharmaceuticals (NASDAQ:TNFA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 19th. The company reported ($18.00) earnings per share (EPS) for the quarter.

TNF Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.